Search

Displaying results 1791 - 1800 of 10000 in total
  1. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    [A236544] So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. … [A236519,L34739] Patients with kidney disease, would originally be given [spironolactone] or [eplerenone] to antagonize the mineraclocorticoid receptor.

    Categories: Mineralocorticoid Receptor Antagonists, Nonsteroidal Mineralocorticoid-Receptor Antagonist
  2. Drug

    Norgestrel

    go.drugbank.com/drugs/DB09389
    Approved

    However, only the levorotary enantiomer ([levonorgestrel]) is biologically active.

    Categories: Sex Hormones and Modulators of the Genital System
  3. Drug

    Bentoquatam

    go.drugbank.com/drugs/DB00516
    Approved

    Bentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak. … Bentoquatam contains bentonite, a clay, and is only effective as long as the film is visible on the skin.

  4. Drug

    Droperidol

    go.drugbank.com/drugs/DB00450
    ApprovedInvestigationalVet approved

    It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the … A butyrophenone with general properties similar to those of haloperidol.

    Categories: Adrenergic alpha-1 Receptor Antagonists, Dopamine D2 Receptor Antagonists
  5. Drug

    Ethambutol

    go.drugbank.com/drugs/DB00330
    ApprovedInvestigational

    Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. … [L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.

    Mixtures: PRO TB 4Products: E-BUTOL TABLET 400 mg
  6. Drug

    Carbimazole

    go.drugbank.com/drugs/DB00389
    Approved

    Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.

  7. Drug

    Tacrine

    go.drugbank.com/drugs/DB00382
    ApprovedWithdrawn

    A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous … Tacrine has been discontinued for the United States market.

  8. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. … [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471]

    Products: CAMZYOS® 2.5MG CAPSULAS DURAS DE LIBERACIÓN INMEDIATA.
  9. Drug

    Tideglusib

    go.drugbank.com/drugs/DB12129
    ApprovedInvestigationalWithdrawn

    Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. … It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).

  10. Drug

    Diazoxide

    go.drugbank.com/drugs/DB01119
    ApprovedInvestigational

    [A190372] Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. … [A190372] When administered intravenously, diazoxide can be used to treat hypertensive emergencies;[L44622] however, this specific form of diazoxide is no longer available in the US.